Integrated <i>in silico</i> and <i>in vitro</i> screening approaches for the discovery of small-molecule inhibitors of β-carbonic anhydrases
β-CAs represent a tractable yet underexploited antibacterial target class. Successful translation will depend on improving bacterial penetration, pharmacokinetics, and target engagement. When strategically positioned as adjunctive or context-dependent therapies, β-CA inhibitors may contribute to the treatment of drug-resistant bacterial infections, including tuberculosis.
Authors
- Ashok Aspatwar (ORCID: https://orcid.org/0000-0002-6938-7835)
- Ratul Bhowmik (ORCID: https://orcid.org/0000-0002-7013-7323)
- Andrea Angeli
- Ilaria D’Agostino
Institutions
- University of Pisa (IT)
- Tampere University (FI)
- University of Florence (IT)
Publication Details
- Journal
- Expert Opinion on Drug Discovery
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1080/17460441.2026.2636772
- Primary Topic
- Enzyme function and inhibition
- Type
- article
- Field-Weighted Citation Impact
- 0.00